The goal is to implement research results into society.
The Department of Regenerative Medicine at Shiga University of Medical Science collaborates with Biozipcode, Inc. as part of an industry-academia partnership. The goal is for Biozipcode, Inc. to implement the research results led by Special Professor Hideto Kojima and Special Professor Takahiko Nakagawa into society.
The term “implementation into society” comes from the concept of “social technology.” It means applying and developing research results to solve social problems.
*On January 24, 2023, all shares of Biozipcode, Inc. were transferred to Mr. Fumihisa Kojima, making it a privately owned company.
*On April 1, 2024, Biozipcode, Inc. became an affiliate of KIYAN MEDICAL Co., Ltd. through capital increase.
About Collaborative(Joint) Research
Collaborative research is a system where universities and private institutions conduct joint research on common issues as equals. Universities receive researchers and research funds from private institutions to produce excellent research results through external collaboration.
The research conducted by the faculty of Shiga University of Medical Science is commissioned by Biozipcode、Inc. The costs are borne by Biozipcode, Inc., except for donations to the Department of Regenerative Medicine.
About COI
For common guidelines on conflicts of interest (COI) in medical research, please refer to this page (Japanese Diabetes Society – COI Guidelines).
In Japan, industry-academia collaboration is promoted as part of efforts to become a nation built on scientific and technological innovation. Collaborative research and technology transfer with companies are to be properly promoted to return research results from universities and public research institutions to society.
On the other hand, when multiple activities are carried out, conflicts of interest can arise among involved individuals and institutions. This is inevitable and unavoidable as research activities and industry-academia collaboration become more active.
Therefore, appropriate COI management, including disclosure, is conducted in collaborative research courses.
*For guidelines on research, refer to the Ministry of Health, Labour and Welfare.
Biozipcode, Inc.
Goodbye. Diabetes.
Aiming to cure diseases, not just treat them, with “medications that cure diabetes” and “cell targeting technology to deliver drugs to specific cells.”
KIYAN MEDICAL Co., Ltd.
DNA of a Pharmaceutical Manufacturer and R&D Company
Established in October 2023, KIYAN MEDICAL Co., Ltd. can conduct the entire drug discovery business. The company provides an environment that allows handling everything from research and development to clinical trials and societal implementation, all in-house, leveraging university research.
Laboratory
Applying the unique technology developed by Professor Kojima, efforts include the redevelopment of existing drugs, development of new drugs, and etc.
Research is conducted daily to understand why diseases do not heal, find answers, and develop cures rather than treatments.
Introducing the research course and related members. Detailed information on each member’s expertise, research content, and achievements is provided.
Research commissioned by Biozipcode Inc. and conducted by Shiga University of Medical Science faculty. Expenses are covered by the commissioning party.
A list of papers published by the lab is available. Research outcomes led by Special Professor Kojima in diabetes and regenerative medicine are presented.
Directions to Shiga University of Medical Science and the lab. Note: JR Seta Station does not accommodate express trains. Please use rapid or local trains.
Frequently asked questions about the Department of Regenerative Medicine, diabetes stem cells, and research content are compiled.
Are You Interested in Research at the Department of Regenerative Medicine?
Are You Interested in Research at the Department of Regenerative Medicine?
You can send a direct inquiry to the Department of Regenerative Medicine through the contact form.
